By reason of the imminent launch of Ximluci® in Europe, Xbrane Biopharma AB invites to a Capital Markets Day on September 22, 2022

Corporate Information




Other Corporate Information

Stockholm, Sweden – Xbrane Biopharma AB (publ) (Nasdaq Stockholm: XBRANE), invites analysts, investors and the media to its Capital Markets Day on September 22, 2022 by reason of EMA's positive opinion for ranibizumab biosimilar candidate Ximluci® (Xlucane®) and the now imminent launch in Europe.

The Capital Markets Day will be held in the Nils Ringertz hall, Biomedicum, floor 3, Solnavägen 9, Solna, starting at 2 pm and will also be broadcast digitally. Refreshments are served from 1.30 pm.

Please register your personal participation at: and digital participation by following the link: